Every 8-K that Supernus Pharmaceuticals, Inc. (SUPN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SUPN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SUPN filings page.
Supernus Pharmaceuticals describes communications about a proposed all-stock merger of equals with Indivior Pharmaceuticals to create a diversified U.S. CNS biopharmaceutical company. A joint investor presentation cites combined net revenue of $2,162 million for the twelve months ended June 30, 2026, from 11 commercial products spanning addiction, psychiatry and neurology, including SUBLOCADE, Qelbree, GOCOVRI and ZURZUVAE.
Management indicates the transaction is expected to close in Q4, subject to stockholder approvals, regulatory clearances and other customary conditions, with Indivior preparing a Form S-4 and joint proxy statement/prospectus. Internal messages tell employees it is business as usual, with roles and employment status unchanged for now and Supernus leadership joining the combined leadership team. Extensive forward-looking disclosures outline risks such as the merger not closing, fixed exchange-ratio exposure, additional indebtedness to fund a Special Dividend, integration and retention challenges, possible termination fees and stockholder litigation, and broader macroeconomic and regulatory uncertainties.
Supernus Pharmaceuticals, Inc. is presenting information on a proposed merger of equals with Indivior Pharmaceuticals Inc., supported by a conference call and webcast at 8:30 a.m. Eastern Time on August 3, 2026. The slides used for this presentation are filed as Exhibit 99.1.
Indivior intends to file a registration statement on Form S-4 that will include a joint proxy statement/prospectus to be sent to both companies’ stockholders. The disclosure includes extensive forward-looking statements highlighting that completion of the merger depends on stockholder and regulatory approvals, satisfaction of closing conditions, potential additional indebtedness to fund a Special Dividend, integration challenges, possible competing proposals, and the risk the transaction may not be completed.
Supernus Pharmaceuticals reported strong second quarter 2026 growth, with total revenues of $219.1 million, a 32% increase from $165.5 million a year earlier. Growth was driven by CNS products including Qelbree, GOCOVRI, ZURZUVAE and ONAPGO, which together generated $175.7 million, up 52% year over year.
Despite higher revenue, Supernus recorded an operating loss of $58.0 million and a net loss of $58.4 million, or $1.01 per share, largely due to a non-cash $54.9 million impairment charge related to APOKYN and higher selling, general and administrative expenses. Adjusted operating earnings were $31.2 million versus $40.9 million in 2025. Cash, cash equivalents and current marketable securities rose to $372.1 million as of June 30, 2026.
Management raised full-year 2026 guidance, targeting total revenues of $860–$890 million and adjusted operating earnings of $150–$180 million. Supernus also highlighted a previously announced all-stock merger of equals with Indivior Pharmaceuticals to create a larger diversified CNS biopharmaceutical company, subject to stockholder and regulatory approvals.
Supernus Pharmaceuticals agreed to a tax-free, all-stock merger of equals with Indivior Pharmaceuticals. Each Supernus share will convert into 1.5401 Indivior shares, with Indivior stockholders owning about 56.5% of the combined company and Supernus stockholders about 43.5%. The combined company will be renamed Supernus, Inc. and its stock is expected to continue trading on Nasdaq under the ticker SUPN.
Indivior will declare a pre-closing special cash dividend of $1.0 billion, funded by a committed $650 million senior secured term loan and available cash. The businesses report approximately $2.2 billion of combined annual revenues and expect $125 million in annual cost synergies. Closing is targeted for the fourth quarter of 2026, subject to stockholder approvals, regulatory clearances, effectiveness of an S-4 registration, Nasdaq listing of new shares, and financing. The agreement includes reciprocal termination fees of $101 million (Supernus) and $174 million (Indivior) and a new employment agreement under which Jack Khattar will serve as CEO of the combined company.
Supernus Pharmaceuticals, Inc. plans to report its second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026. The company will host a conference call and webcast that day at 4:30 p.m. ET to review the results and take questions.
The live webcast will be available in the Events & Presentations section of the company’s investor relations website, with registration providing dial-in details. A replay of the call will remain accessible on the site for 60 days. Supernus describes itself as a biopharmaceutical company focused on developing and commercializing treatments for a range of central nervous system diseases, including ADHD, Parkinson’s disease-related conditions, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Supernus Pharmaceuticals, Inc. reported the results of its 2026 annual stockholder meeting, where all four proposals received the required support. Stockholders elected Class I directors Frederick M. Hudson and Charles W. Newhall, III to terms ending at the 2029 annual meeting.
Stockholders approved, on a non-binding basis, the compensation of the company’s named executive officers and ratified KPMG LLP as independent public accounting firm for the fiscal year ending December 31, 2026. They also approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares available under the plan. There were 58,039,721 shares of common stock outstanding and entitled to vote as of April 29, 2026.
Supernus Pharmaceuticals, Inc. has become obligated to pay a milestone under its Contingent Value Rights Agreement after Milestone 1 was achieved on March 18, 2026. The payment is equal to $0.50 per Contingent Value Right (CVR), for an aggregate of approximately $33.4 million.
The milestone payment will be made in cash, without interest and subject to applicable withholding taxes. Supernus will deposit the funds with the rights agent within 20 business days of May 17, 2026, and the rights agent will distribute payments to CVR holders under the terms of the CVR Agreement.
Supernus Pharmaceuticals reported strong growth for the first quarter of 2026, with total revenues of $207.7 million, up 39% from $149.8 million a year earlier. Revenues from commercial products, including collaboration revenue from ZURZUVAE, reached $178.4 million, a 26% increase.
Growth was driven by key CNS products: Qelbree net sales rose 20% to $77.9 million, GOCOVRI grew 15% to $35.2 million, ONAPGO generated $8.4 million after launch, and ZURZUVAE collaboration revenue contributed $27.6 million. The company posted a GAAP net loss of $2.3 million (or $0.04 per share), narrowed from $11.8 million, while non-GAAP adjusted operating earnings improved to $28.7 million. Cash, cash equivalents, and current marketable securities increased to $384.2 million as of March 31, 2026. Supernus reiterated its full-year 2026 guidance, including total revenues of $840–$870 million and non-GAAP adjusted operating earnings of $140–$170 million.
Supernus Pharmaceuticals, Inc. filed a current report stating it will release its first quarter 2026 financial and business results after the market closes on Tuesday, May 5, 2026. Management will host a conference call and webcast that day at 4:30 p.m. ET to discuss the results and take questions.
The live webcast and a replay, available for 60 days, will be accessible through the Investor Relations section of the company’s website. The filing also reiterates that Supernus is a biopharmaceutical company focused on treatments for a range of central nervous system diseases, including ADHD, Parkinson’s disease–related conditions, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Supernus Pharmaceuticals, Inc. entered into and completed an asset purchase agreement with Navitor Pharmaceuticals, Inc. and Navitor Pharmaceuticals, LLC to acquire all rights to the compound known as NV-5138 or SPN-820, including related intellectual property, inventory, regulatory materials, data, contracts and goodwill.
The purchase price consists of Supernus completing one Phase 2b study and potentially paying up to $350 million in milestone payments tied to specific development, regulatory and commercial achievements, using commercially reasonable efforts to reach those milestones. If Supernus determines after the Phase 2 study that it was not successful, it has no further obligation to pursue milestones or commercialization of the compound.
The agreement includes customary representations, warranties, covenants and indemnification provisions, allows Supernus to offset indemnification losses against unpaid or previously paid milestone amounts, and imposes a five‑year post‑closing non‑competition and non‑solicitation covenant on the restricted parties.
Supernus Pharmaceuticals updated compensation for key executives following its annual review. The Board increased CEO Jack Khattar’s annual base salary from $1,036,000 to $1,067,100, awarded a 2025 cash bonus of $846,930, and granted options for 341,610 shares plus 204,966 performance share units that vest based on performance goals.
Other senior executives received base salary increases, 2025 cash bonuses, and equity awards combining stock options, restricted stock units, and performance share units. Option and RSU grants vest in equal annual installments over four years at an exercise price of $50.20 per share, while PSU vesting depends on performance as certified by the Compensation Committee.
Supernus Pharmaceuticals reported record revenue for both the fourth quarter and full year 2025 but moved from profit to loss due mainly to acquisition-related costs. Total revenues reached $211.6 million in Q4 2025, up 21% year over year, and $719.0 million for 2025, up 9%.
Growth products were the main driver, with combined revenues of $161.3 million in Q4 and $521.8 million for 2025, rising 45% and 40%. Newer assets performed strongly: ONAPGO generated $8.9 million in Q4 sales after its April launch and ZURZUVAE collaboration revenue was $32.8 million. However, 2025 GAAP operating results swung to a $62.3 million loss and net loss of $38.6 million, largely reflecting approximately $72.9 million in costs tied to the Sage Therapeutics acquisition and higher amortization and contingent consideration. Adjusted operating earnings were $158.7 million. Cash, cash equivalents and marketable securities were $308.7 million at year-end, after funding the Sage deal. For 2026, Supernus guides to total revenues of $840–$870 million, GAAP operating earnings of $0–$30 million, and adjusted operating earnings of $140–$170 million.
Supernus Pharmaceuticals, Inc. filed a Form 8-K to announce when it will release its next financial update. The company expects to report fourth quarter and full year 2025 financial and business results after the market closes on Tuesday, February 24, 2026.
Management, including the President and CEO Jack Khattar and Senior Vice President and CFO Tim Dec, will host a conference call and webcast on February 24, 2026 at 4:30 p.m. ET to discuss these results and answer questions. A live webcast and a 60-day replay will be available through the Investor Relations section of the company’s website.
Supernus Pharmaceuticals, Inc. reported that on January 22, 2026 it entered into a First Amendment to its September 12, 2018 Agreement and Plan of Merger, with Reich Consulting Group, Inc. acting as Securityholder Representative.
The amendment changes the timing and payment of certain merger-related milestones. Supernus is filing the amendment as Exhibit 10.1, with limited portions omitted as confidential under Regulation S-K Item 601(b)(10)(iv), which the company states are not material and would be competitively harmful if publicly disclosed.
Supernus Pharmaceuticals (SUPN) furnished an 8-K announcing Q3 2025 results and a supply update for ONAPGO. The company furnished a press release with financial results for the quarter ended September 30, 2025, and hosted a live webcast at 4:30 p.m. Eastern Time on November 4. The webcast will be archived on the company’s website for 60 days.
Supernus also disclosed a temporary supply constraint for ONAPGO driven by stronger than expected demand. To manage the imbalance, the company is prioritizing care for patients currently on therapy and pausing delivery to patients who have not yet started ONAPGO. Supernus is working to build inventory and aims to resume new patient initiations as soon as possible, with updates to follow.
Supernus Pharmaceuticals (SUPN) announced it will report third quarter 2025 results after the market closes on November 4, 2025.
Management will host a conference call and webcast on November 4, 2025 at 4:30 p.m. ET to discuss its financial and business results.
The announcement was furnished via a press release included as Exhibit 99.1.
Supernus Pharmaceuticals filed an amended current report to add required financial statements and pro forma information related to its acquisition of Sage Therapeutics. The deal followed a tender offer at $8.50 per share in cash plus one CVR per share, which can pay up to $3.50 per share if specified milestones are achieved by June 30, 2026; December 31, 2027; December 31, 2028; and December 31, 2030. The offer expired on July 30, 2025, was accepted and paid, and Sage merged into a Supernus subsidiary on July 31, 2025 under Section 251(h), becoming a wholly owned subsidiary.
The amendment supplies Sage’s audited 2023–2024 financials, unaudited interim financials for the three and six months ended June 30, 2024 and 2025, and unaudited pro forma condensed combined statements, including a balance sheet as of June 30, 2025 and statements of operations for the six months ended June 30, 2025 and the year ended December 31, 2024, plus a PwC consent. The pro formas are presented for informational purposes only.